摘要:
The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.
摘要:
A compound of formula (I): wherein R1-R3 are as defined in the specification, and compositions, combinations, and methods of manufacture, and methods of treatment of inflammatory diseases, using the same.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof.The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof.The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof.The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
摘要:
A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
摘要:
A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
摘要:
A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.
摘要:
A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor. The adenosine derivative has a general formula (I) as follows: